Journal
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
Volume 33, Issue 3, Pages S155-S158Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/IOP.0000000000000509
Keywords
-
Categories
Funding
- Research to Prevent Blindness, Inc., New York
Ask authors/readers for more resources
In this case report, the clinical presentation of an inflammatory orbitopathy seen following treatment with ipilimumab is described.After 3 rounds of ipilimumab (10 mg/ kg) treatment for Stage III metastatic melanoma, the subject of this case report developed acute eye pain and proptosis. At initial presentation, she had marked proptosis and diffuse severe ophthalmoparesis. After treatment with high-dose steroids, over a period of 6 months, the symptoms gradually resolved fully. Although the condition may mimic thyroidassociated orbitopathy, imaging and laboratory features suggest that the orbitopathy associated with ipilimumab is not a secondary effect of thyroid dysfunction but a distinct inflammatory condition. The authors conclude that immunerelated side effects can occur with biologic agents used to treat malignancies and these side-effects can involve the eye. This case illustrates the occurrence of an inflammatory orbitopathy associated with ipilimumab treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available